More on Questcor Pharmaceuticals (QCOR): Q4 beats on all counts as total revenue jumped 113%...


More on Questcor Pharmaceuticals (QCOR): Q4 beats on all counts as total revenue jumped 113% Y/Y, primarily due to expanded Acthar prescriptions in the treatment of nephrotic syndrome as well as the treatment of MS relapses and infantile spasms. Net sales also benefited from the initiation of commercial activities focused on the use of Acthar in the treatment of rheumatology-related conditions. Despite the overall better numbers, the shares are -6.6% AH.

From other sites
Comments (11)
  • vireoman
    , contributor
    Comments (1266) | Send Message
     
    Shares are purportedly down because fewer vials of Acthar were sold for treatment of MS in Q4 (down 8%). However, total vials sold increased every quarter of 2012: Q1-4,111; Q2-4,710; Q3-5,590; and, Q4-6,330. So, the increased usage of Acthar for nephrotic syndrome and rheumatology evidently made up the difference. In addition, QCOR increased its rheumatology sales force from 12 to 55 in Q4, so a further increase in sales can be expected. And they raised their dividend by 25%.

     

    Sell away. I wouldn't mind adding to my currently small stake in QCOR.
    26 Feb 2013, 08:12 PM Reply Like
  • Zachary Schenk
    , contributor
    Comments (100) | Send Message
     
    Got in a great price AH, thanks to the (dumb) price drop;
    26 Feb 2013, 08:45 PM Reply Like
  • Michael Bryant
    , contributor
    Comments (7235) | Send Message
     
    Wish I had.
    26 Feb 2013, 11:58 PM Reply Like
  • pharmaman58
    , contributor
    Comments (97) | Send Message
     
    Read the cc transcript and then do yourself a favor and buy QCOR before hours on 2/27.
    26 Feb 2013, 10:30 PM Reply Like
  • Evanmetzger
    , contributor
    Comment (1) | Send Message
     
    I like this company. Why Does it seem there is a market bias against it? I would like to take a long position based on fundamentals. Can someone enlighten me as to why there seems to be some resistance in the market. Thanks for any help.
    27 Feb 2013, 03:10 AM Reply Like
  • joeclarke9@aol.com
    , contributor
    Comments (20) | Send Message
     
    Q4 beats and shares DOWN ? Why ? anyone know ?
    27 Feb 2013, 05:55 AM Reply Like
  • dieuwer
    , contributor
    Comments (2946) | Send Message
     
    Manipulation
    27 Feb 2013, 08:30 AM Reply Like
  • Michael Bryant
    , contributor
    Comments (7235) | Send Message
     
    Analysts.

     

    Disappointed speculators.
    27 Feb 2013, 08:32 AM Reply Like
  • simgold11
    , contributor
    Comments (9) | Send Message
     
    Without checking, my guess is further manipulation by Andrew Left of
    Citron Research. This short seller has been on a mission to downgrade the stock, and it fits the convicted felon's pattern.
    27 Feb 2013, 12:50 PM Reply Like
  • Michael Bryant
    , contributor
    Comments (7235) | Send Message
     
    Question: If he is a convicted felon, why is he lose? I would be careful of releasing a convict. If he was convicted of manipulation, ban him from using a computer.
    27 Feb 2013, 10:20 PM Reply Like
  • pharmaman58
    , contributor
    Comments (97) | Send Message
     
    Take a careful look at QCOR. Analysts are missing the boat here with their projected EPS and target price. My 2013 target is $6 and change. Other longtime biotech investors have posted similar projections or higher.

     

    This is a company with no debt, a dramatically expanded sales force coming on line, focused management and considerable runway with their FDA-approved indications for the most challenged patients across several disease states.
    3 Mar 2013, 07:50 AM Reply Like
DJIA (DIA) S&P 500 (SPY)
ETF Hub
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs